WHAT IS CLAIMED IS:

~~1. The compound N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl) piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263 free base) in a solid crystalline form.~~

~~2.~~1. The compound ~~of Claim 1~~ N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl) piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263 free base) in a solid crystalline form, wherein the crystalline form is Form I ABT-263 free base, characterized at least by a powder X-ray diffraction peak at any one or more of the following positions: 6.21, 6.72, 12.17, 18.03 and 20.10° 2θ, ± 0.2° 2θ.

~~3.~~2. The compound of Claim ~~2~~1, wherein the crystalline form is Form I ABT-263 free base, characterized at least by a powder X-ray diffraction peak at each of said positions.

~~4.~~3. The compound of Claim ~~2~~1, wherein the crystalline form is Form I ABT-263 free base, characterized at least by a powder X-ray diffraction peak at each of the following positions: 6.21, 6.72, 9.66, 10.92, 11.34, 12.17, 14.28, 16.40, 16.95, 17.81, 18.03, 18.47, 19.32, 20.10 and 21.87° 2θ, ± 0.2° 2θ.

~~5.~~4. The compound ~~of Claim 1~~N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl) piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263 free base) in a solid crystalline form, wherein the crystalline form is Form II ABT-263 free base, characterized at least by a powder X-ray diffraction peak at any one or more of the following positions: 5.79, 8.60, 12.76, 15.00 and 20.56° 2θ, ± 0.2° 2θ.

~~6.~~5. The compound of Claim ~~5~~4, wherein the crystalline form is Form II ABT-263 free base, characterized at least by a powder X-ray diffraction peak at each of said positions.

~~7.~~6. The compound of Claim ~~5~~4, wherein the crystalline form is Form II ABT-263 free base, characterized at least by a powder X-ray diffraction peak at each of the following positions: 5.79, 8.60, 9.34, 10.79, 11.36, 11.59, 12.76, 13.23, 13.73, 14.01, 14.72, 15.00, 16.28, 17.07, 17.48, 18.75, 19.34, 19.71, 20.56 and 21.35° 2θ, ± 0.2° 2θ.

~~8.~~7. The compound ~~of Claim 1~~N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl) piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263 free base) in a solid crystalline form, wherein the crystalline form is a solvate comprising ABT-263 free base solvated with an organic solvent.

~~9.~~8. The compound of Claim ~~8~~7, wherein the ~~solvate~~ organic solvent is selected from the group consisting of ethanol/ethyl acetate mixture, 1-propanol, 2-propanol, methanol, benzene, toluene, dioxane/hexanes mixture, methyl acetate/hexanes mixture, chloroform, ethyl acetate, isopropyl acetate, methyl acetate, pyridine, anisole and trifluorotoluene solvates.

~~10.~~9. A pharmaceutical composition comprising the compound ~~of Claim 1~~of any of claims 2, 5, and 8 in a solid crystalline form and one or more pharmaceutically acceptable excipients.

~~11.~~10. A process for preparing a pharmaceutical solution composition of ABT-263, comprising dissolving ~~crystalline ABT-263 free base~~ the compound of any of claims 2, 5, and 8 in a pharmaceutically acceptable solvent or mixture of solvents.

~~12.~~11. The process of Claim ~~11~~10, wherein the crystalline ABT-263 free base comprises Form I ABT-263 free base.

~~13.~~12. The process of Claim 11, wherein the crystalline ABT-263 free base comprises Form II ABT-263 free base.

~~14.~~13. A ~~method for~~composition for use in treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, ~~comprising administering~~ wherein the composition comprises a therapeutically effective amount of the compound of any of claims 2, 5, and 8 and one or more pharmaceutically acceptable excipients and is administered to a subject having the disease ~~a therapeutically effective amount of (a) crystalline ABT-263 free base or (b) a pharmaceutical composition comprising crystalline ABT-263 free base and one or more pharmaceutically acceptable excipients~~; wherein the disease is a neoplastic disease selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder

cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

~~15.~~14. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base~~compound comprises Form I ABT-263 free base.

~~16.~~15. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base~~compound comprises Form II ABT-263 free base.

~~17.~~16. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base~~compound comprises a solvate comprising ABT-263 free base solvated with an organic solvent.

~~18.~~17. The ~~method~~ composition of Claim ~~17~~16, wherein the solvate is selected from the group consisting of ethanol/ethyl acetate mixture, 1-propanol, 2-propanol, methanol, benzene, toluene, dioxane/hexanes mixture, methyl acetate/hexanes mixture, chloroform, ethyl acetate, isopropyl acetate, methyl acetate, pyridine, anisole and trifluorotoluene solvates.

~~19.~~18. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base or pharmaceutical~~ composition is administered by an oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, otic, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular route.

~~20. The method of Claim 14, wherein the disease is a neoplastic disease.~~

~~21. The method of Claim 20, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium,~~

~~carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.~~

~~22.~~ 19. The ~~method~~ composition of Claim ~~20~~13, wherein the neoplastic disease is a lymphoid malignancy.

~~23.~~ 20. The ~~method~~ composition of Claim ~~22~~19, wherein the lymphoid malignancy is non-Hodgkin's lymphoma.

~~24.~~21. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base or pharmaceutical~~ composition is administered orally in a dose of about 50 to about 1000 mg ABT-263 per day at an average treatment interval of about 3 hours to about 7 days.

~~25.~~22. The ~~method~~ composition of Claim ~~14~~13, wherein the ~~crystalline ABT-263 free base or pharmaceutical~~ composition is administered orally once daily in a dose of about 200 to about 400 mg ABT-263 free base equivalent per day.

~~26.~~23. A ~~method for~~ composition for use in treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, ~~comprising~~ wherein the composition is prepared by dissolving ~~crystalline ABT-263 free base~~ a therapeutically effective amount of the compound of any of claims 2, 5, and 8 in a

pharmaceutically acceptable solvent or mixture of solvents, and ~~administering~~ the resulting solution ~~in a therapeutically effective amount~~ is administered to a subject having the disease; wherein the disease is a neoplastic disease selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

~~27.~~24. The ~~method~~ composition of Claim ~~26~~23, wherein the c~~rystalline ABT-263 free base~~compound comprises Form I

ABT-263 free base.

~~28.~~25. The ~~method~~ composition of Claim ~~26~~23, wherein the ~~crystalline ABT-263 free base~~compound comprises Form II ABT-263 free base.

~~29.~~26. The ~~method~~ composition of Claim ~~26~~23, wherein the ~~crystalline ABT-263 free base~~compound comprises a solvate comprising ABT-263 free base solvated with an organic solvent.

~~30.~~27. The ~~method~~ composition of Claim ~~29~~26, wherein the solvate is selected from the group consisting of ethanol/ethyl acetate mixture, 1-propanol, 2-propanol, methanol, benzene, toluene, dioxane/hexanes mixture, methyl acetate/hexanes mixture, chloroform, ethyl acetate, isopropyl acetate, methyl acetate, pyridine, anisole and trifluorotoluene solvates.

~~31.~~28. The ~~method~~ composition of Claim ~~26~~23, wherein the solution is administered by an oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, otic, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular route.

~~32. The method of Claim 26, wherein the disease is a neoplastic disease.~~

~~33. The method of Claim 32, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder~~

~~cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.~~

~~34.~~ 29. The ~~method~~ composition of Claim ~~32~~23, wherein the neoplastic disease is a lymphoid malignancy.

~~35.~~ 30. The ~~method~~ composition of Claim ~~34~~29, wherein the lymphoid malignancy is non-Hodgkin's lymphoma.

~~36.~~ 31. The ~~method~~ composition of Claim ~~26~~23, wherein the solution is administered orally in a dose of about 50 to about 1000 mg ABT-263 per day at an average treatment interval of about 3 hours to about 7 days.

~~37.~~ 32. The ~~method~~ composition of Claim ~~26~~23, wherein the solution is administered orally once daily in a dose of about 200 to about 400 mg ABT-263 free base equivalent per day.